LETROZOLE WITH FOLLICLE STIMULATING HORMONE VERSUS NOLVADEX WITH THE LATTER IN PATIENTS HAVING POLYCYSTIC OVARIAN SYNDROME UNDERGOING INTRA CYTOPLASMIC SPERM INJECTION | ||
| ALEXMED ePosters | ||
| Article 218, Volume 3, Issue 4, December 2021, Pages 49-50 | ||
| Document Type: Preliminary preprint short reports of original research | ||
| DOI: 10.21608/alexpo.2021.95822.1270 | ||
| Author | ||
| Taghread Mohammed Alnakeeb* | ||
| Department of Obstetrics and Gynecology, Faculty of Medicine, Alexandria University | ||
| Abstract | ||
| Poly cystic ovary syndrome Poly cystic ovary syndrome (PCOS) is a widespread endocrine disease that occurs in 20% of women of reproductive age. Ovarian dysfunction continues to be the main feature which makes this syndrome the major cause of anovulatory associated with infertility. In vitro fertilization is an effective treatment after repeated failure of ovulation induction by clomiphene citrate and gonadotrophin. Aromatase inhibitors (Letrozole) selectively inhibit the conversion of androgens to estrogens in granulosa cells of developing ovarian follicles, resulting in a subsequent increase in intra-ovarian androgens and absence of a rise in estrogens. Tamoxifen (Nolvadex) is a nonsteroidal triphenylethylene antiestrogen is used as an ovulation induction agent in Europe. When used as an ovulation induction agent, tamoxifen was typically administered at 20 to 60 mg for 5 days. In this study we will use oral compounds as Letrozole (aromatase inhibitors) in combination with minimal dose of gonadotropins versus Nolvadex (anti-estrogen) in combination with minimal dose of gonadotropins in PCOS women undergoing ICSI. | ||
| Keywords | ||
| Poly cystic ovary syndrome (PCOS); Letrozole; Nolvadex | ||
|
Supplementary Files
|
||
|
Statistics Article View: 103 |
||
